The DOI matches its Crossref record.
Quantitative Deposition of Aerosolized Gentamicin in Cystic Fibrosis
Abstract
In cystic fibrosis (CF), the clinical effectiveness of aerosolized antibiotics is controversial. Previous investigators have not considered the type of nebulizer, droplet size, and dose to the lung in assessing the results of aerosol therapy. The present study tests the importance of these factors by standardizing an aerosol system for delivery of antibiotics and other agents to patients with CF. Particle size, distribution, and output from a commercially available nebulizer were measured. Thirteen patients with CF inhaled aerosol (MMAD = 1.1 micron) containing gentamicin (160 mg in nebulizer) and 99mTc-labeled human serum albumin. Patients' sputum and serum were analyzed for gentamicin levels by immunoenzymatic assay (Emit; Syva Corp., Palo Alto, CA). Using a gamma camera and suitable filters, central versus peripheral deposition (C/P ratio) and whole lung deposition were measured and related to sputum gentamicin levels. Gentamicin deposit averaged 12.3 mg +/- 5.9 (SD) or 7.69% of the original amount placed in the nebulizer. Peak sputum levels averaged 376.6 micrograms/ml +/- 275, whereas serum levels were undetectable in all patients. When peak sputum levels were normalized for the amount deposited, a close correlation with C/P ratio was obtained (r = 0.88, p less than 0.05). Furthermore, an inverse relationship was found between the C/P ratio and the %FEV1 (r = 0.76, p less than 0.05). Finally, a bell-shaped relationship between deposited dose and minute ventilation was seen in the patients (r = 0.88, p less than 0.05), i.e., an optimal minute ventilation was shown. These relationships may be important when designing future clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Labiris, N. R., & Dolovich, M. B. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01892.x · Cited by 1,245
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
Döring, G., Conway, S. P., Heijerman, H. G. M., Hodson, M. E., Høiby, N., Smyth, A., Touw, D. J., & the Consensus Committee, F. (2000) · European Respiratory Journal · doi:10.1034/j.1399-3003.2000.16d30.x · Cited by 620
Early intervention and prevention of lung disease in cystic fibrosis: a European consensus
Döring, G., & Hoiby, N. (2004) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2004.03.008 · Cited by 304
Pharmacokinetics and Bioavailability of Aerosolized Tobramycin in Cystic Fibrosis
Geller, D. E., Pitlick, W. H., Nardella, P. A., Tracewell, W. G., & Ramsey, B. W. (2002) · Chest · doi:10.1378/chest.122.1.219 · Cited by 300
Heijerman, H., Westerman, E., Conway, S., & Touw, D. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.005 · Cited by 264
Metadata
- Authors
- Ilowite, J. S., Gorvoy, J. D., & Smaldone, G. C.
- Venue
- American Review of Respiratory Disease
- Publisher
- Oxford University Press (OUP)
- Published
- 1987-12
- Volume
- 136
- Issue
- 6
- Pages
- 1445-1449
- ISSN
- 0003-0805 (ISSN-L)
- OpenAlex
- W2033241761
- Cited by
- 247
- References
- 0
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quantitative Deposition of Aerosolized Gentamicin in Cystic Fibrosis. https://app.cochat.ai/papers/10.1164/ajrccm/136.6.1445
- The paper
- Ilowite, J. S., Gorvoy, J. D., & Smaldone, G. C. (1987). Quantitative Deposition of Aerosolized Gentamicin in Cystic Fibrosis. American Review of Respiratory Disease. https://doi.org/10.1164/ajrccm/136.6.1445
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.